Andrea Mari
Andrea Mari
Institute of Neuroscience
Bestätigte E-Mail-Adresse bei cnr.it
TitelZitiert vonJahr
A model-based method for assessing insulin sensitivity from the oral glucose tolerance test
A Mari, G Pacini, E Murphy, B Ludvik, JJ Nolan
Diabetes care 24 (3), 539-548, 2001
6982001
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
E Ferrannini, E Muscelli, S Frascerra, S Baldi, A Mari, T Heise, UC Broedl, ...
The Journal of clinical investigation 124 (2), 499-508, 2014
5972014
How to measure insulin sensitivity
E Ferrannini, A Mari
Journal of hypertension 16 (7), 895-906, 1998
5761998
β-Cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis
E Ferrannini, A Gastaldelli, Y Miyazaki, M Matsuda, A Mari, RA DeFronzo
The Journal of Clinical Endocrinology & Metabolism 90 (1), 493-500, 2005
5072005
Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed β-cell function in patients with type 2 diabetes
A Mari, WM Sallas, YL He, C Watson, M Ligueros-Saylan, BE Dunning, ...
The Journal of Clinical Endocrinology & Metabolism 90 (8), 4888-4894, 2005
4232005
Mechanisms of recovery from type 2 diabetes after malabsorptive bariatric surgery
C Guidone, M Manco, E Valera-Mora, A Iaconelli, D Gniuli, A Mari, ...
Diabetes 55 (7), 2025-2031, 2006
4132006
Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients
E Muscelli, A Mari, A Casolaro, S Camastra, G Seghieri, A Gastaldelli, ...
Diabetes 57 (5), 1340-1348, 2008
3652008
Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients
E Muscelli, A Mari, A Casolaro, S Camastra, G Seghieri, A Gastaldelli, ...
Diabetes 57 (5), 1340-1348, 2008
3632008
Pancreatic fat content and β-cell function in men with and without type 2 diabetes
ME Tushuizen, MC Bunck, PJ Pouwels, S Bontemps, ...
Diabetes care 30 (11), 2916-2921, 2007
3092007
Meal and oral glucose tests for assessment of β-cell function: modeling analysis in normal subjects
A Mari, O Schmitz, A Gastaldelli, T Oestergaard, B Nyholm, E Ferrannini
American Journal of Physiology-Endocrinology and Metabolism 283 (6), E1159-E1166, 2002
3002002
Visceral fat in hypertension: influence on insulin resistance and β-cell function
AM Sironi, A Gastaldelli, A Mari, D Ciociaro, V Postano, E Buzzigoli, ...
Hypertension 44 (2), 127-133, 2004
2812004
The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients
B Balas, MR Baig, C Watson, BE Dunning, M Ligueros-Saylan, Y Wang, ...
The Journal of Clinical Endocrinology & Metabolism 92 (4), 1249-1255, 2007
2612007
Methods for clinical assessment of insulin sensitivity and β-cell function
G Pacini, A Mari
Best Practice & Research Clinical Endocrinology & Metabolism 17 (3), 305-322, 2003
2602003
Common variants of the novel type 2 diabetes genes CDKAL1 and HHEX/IDE are associated with decreased pancreatic β-cell function
L Pascoe, A Tura, SK Patel, IM Ibrahim, E Ferrannini, E Zeggini, ...
Diabetes 56 (12), 3101-3104, 2007
2332007
Beta cell function and its relation to insulin action in humans: a critical appraisal
E Ferrannini, A Mari
Diabetologia 47 (5), 943-956, 2004
2332004
Non-steady state: error analysis of Steele's model and developments for glucose kinetics
C Cobelli, A Mari, E Ferrannini
American Journal of Physiology-Endocrinology And Metabolism 252 (5), E679-E689, 1987
2261987
Restoration of early rise in plasma insulin levels improves the glucose tolerance of type 2 diabetic patients.
D Bruttomesso, A Pianta, A Mari, A Valerio, MC Marescotti, A Avogaro, ...
Diabetes 48 (1), 99-105, 1999
2231999
Thiazolidinediones improve β-cell function in type 2 diabetic patients
A Gastaldelli, E Ferrannini, Y Miyazaki, M Matsuda, A Mari, RA DeFronzo
American Journal of Physiology-Endocrinology and Metabolism 292 (3), E871-E883, 2007
2182007
Early metabolic markers of the development of dysglycemia and type 2 diabetes and their physiological significance
E Ferrannini, A Natali, S Camastra, M Nannipieri, A Mari, KP Adam, ...
Diabetes 62 (5), 1730-1737, 2013
2052013
Early metabolic markers of the development of dysglycemia and type 2 diabetes and their physiological significance
E Ferrannini, A Natali, S Camastra, M Nannipieri, A Mari, KP Adam, ...
Diabetes 62 (5), 1730-1737, 2013
2052013
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20